Recent News

UNC Lineberger spring developmental grants awarded, fall applications due Sept. 15

UNC Lineberger spring developmental grants awarded, fall applications due Sept. 15

Thirteen research teams will receive grants through the spring 2016 cycle of the UNC Lineberger Developmental Grants program. The deadline for applying for the next round of funding is 5 p.m. Thursday, Sept. 15.

UNC Lineberger spring developmental grants awarded, fall applications due Sept. 15 - Read More…

NIH Precision Medicine Initiative Cohort Research Program appoints Chung to Institutional Review Board

NIH Precision Medicine Initiative Cohort Research Program appoints Chung to Institutional Review Board

UNC Lineberger's Arlene Chung, MD, MHA, MMCi, will serve as an inaugural member of the NIH Precision Medicine Initiative Cohort Program Institutional Review Board.

NIH Precision Medicine Initiative Cohort Research Program appoints Chung to Institutional Review Board - Read More…

Blood cancer treatment may age immune cells as much as 30 years

Blood cancer treatment may age immune cells as much as 30 years

Researchers led by UNC Lineberger Director Norman Sharpless, MD, and William Wood, MD, uncovered clues that suggest that stem cell transplant is linked to a marked increase in the “molecular age” of these immune cells in a group of patients with blood cancer.

Blood cancer treatment may age immune cells as much as 30 years - Read More…

Researchers question process for reviewing coverage of ‘off label’ cancer drug use

Researchers question process for reviewing coverage of ‘off label’ cancer drug use

In a paper published online by the Journal of the American Medical Association, UNC Lineberger physician-researchers led by Ethan Basch, MD, MSc, raised concerns that there are inconsistencies between the five reference guides, or compendia, that the Centers for Medicare and Medicaid Services uses to determine which drugs it will reimburse for off-label uses in cancer care.

Researchers question process for reviewing coverage of ‘off label’ cancer drug use - Read More…